Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner, even in patients with difficult-to-treat disease Four real-world study posters illustrate significant burden of depression and ASM... Read More

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the... Read More

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual... Read More

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company’s Na V 1.1 program in Dravet syndrome VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE... Read More

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare Conference Thursday, November... Read More

Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit Phase 1 Nav1.7 & Kv7 studies underway Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch Conference call at 4:30 pm ET today... Read More

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial... Read More

Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced... Read More

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 77,750 share options. All of... Read More

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential... Read More

VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 55,300 share options. All of... Read More

Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch... Read More

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc . (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday,... Read More

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options... Read More

VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution,... Read More

VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc . (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,750 share options. All of the foregoing share... Read More

Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc . (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing... Read More

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025.... Read More

VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 53,550 share options. All of the foregoing share... Read More

VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025.... Read More

Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 IND filing... Read More

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May... Read More

VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units... Read More

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meeting Long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS) Exploratory analysis of efficacy of azetukalner in FOS seizure sub-types Patient survey findings on mental health and comorbidity burdens of FOS VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE)... Read More

VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025. Fireside Chat Presentation Details:... Read More

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025... Read More

VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025. Fireside Chat... Read More

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. Conference... Read More

Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner First of three planned Phase 3 MDD studies now initiated Expanding ion channel portfolio includes Kv7 and Nav1.7 candidates advancing towards IND filings in 2025 VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.... Read More

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.... Read More

OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 Patient-reported... Read More

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOS New pre-clinical data from the Company’s Nav1.1 program VANCOUVER, British Columbia and BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to... Read More

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 9:10 a.m.... Read More

Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 Recent appointment of Matt Ronsheim, experienced... Read More

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. Conference... Read More

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024. Fireside Chat... Read More

Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster... Read More

VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr.... Read More

Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 MDD program on track with Phase 3 study expected to initiate in H2 2024 Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused... Read More

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference... Read More

VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL. Fireside Chat Presentation Details: Date: Wednesday, June 12, 2024 Time: 4:00 pm Eastern Time Webcast: Register here... Read More

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer,... Read More

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British... Read More

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation Details: Date: Wednesday, May 15, 2024 Time: 3:40 pm Pacific Time (6:40 pm Eastern Time) Webcast:... Read More

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY. Fireside Chat Presentation Details: Date: Tuesday, May 14, 2024 Time: 3:35 pm Eastern Time Webcast: Register here... Read More

VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information: Date: Thursday, May 9, 2024 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)... Read More

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on... Read More

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024. Company Presentation Details: Date: Tuesday, April 16, 2024 Time: 9:30 AM Eastern Time Webcast: Register here Presenters: Ian Mortimer,... Read More

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23 rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024. Company Fireside Chat Presentation Details: Date: Thursday, April 11, 2024 Time: 3:00 PM Eastern Time Webcast: Register here Presenters:... Read More

VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event. Company Fireside Chat Presentation Details: Date: Tuesday, March 19, 2024 Time: 12:30-12:55 PM Eastern Time Webcast: Register here Presenters: Sherry Aulin, Chief Financial Officer Chris... Read More

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024. Company Fireside Chat Presentation Details: Date: Monday, March 11, 2024 Time: 11:20 AM Eastern Time Webcast: Register here... Read More

XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned “end-of-Phase 2” meeting with the FDA in April to support the initiation of XEN1101 Phase 3 program in major depressive disorder in the second half of the year Strong financial... Read More

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2023 financial and operating results after the close of U.S. financial markets on Thursday, February 29, 2024. Conference Call/Webcast Information: Date: Thursday, February 29, 2024 Time: 4:30 pm Eastern Time... Read More

Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for Initiation in 2024 VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined progress within its pipeline programs and... Read More

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024. Company Presentation Details: Date: Monday, January 8, 2024 Time: 9-9:40 AM Pacific Time (12-12:40 PM Eastern Time)... Read More

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to... Read More

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Xenon will have another strong presence at AES this year, with many... Read More

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement.... Read More

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration... Read More

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major... Read More

VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that its partner, Neurocrine Biosciences, Inc., reported today that the Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures (FOS) failed to demonstrate meaningful reduction in seizure frequency. Neurocrine Biosciences guided that... Read More

Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Patient enrollment in X-TOLE2 expected to complete in the second half of 2024 Conference call at 4:30 pm ET today VANCOUVER, British... Read More

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023. Conference Call/Webcast Information: Date: Wednesday, November 8, 2023 Time: 4:30 pm Eastern Time (1:30 pm Pacific... Read More

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy. Importantly, the efficacy and safety... Read More

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neuro Summit to be held on October 11, 2023. Company Fireside Chat Presentation Details: Date: Wednesday, October 11, 2023 Time: 2:25 PM Eastern Time Webcast: Register here Presenters: Ian... Read More

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023. Company Fireside Chat Presentation Details: Date: Wednesday, September 20, 2023 Time: 4:20 pm Eastern Time Webcast: Register... Read More

VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key opinion leaders (KOLs) focused on major depressive disorder. Webinar : “XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs” Date : Tuesday, September 19, 2023... Read More

New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales Oral presentations showcase Phase 3 clinical trials in focal onset seizures and... Read More

VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Wells Fargo 2023 Healthcare Conference to be held September 6-8, 2023. Company Fireside Chat Presentation Details: Date: Wednesday, September 6, 2023 Time: 2:15 pm Eastern Time Webcast: Register here Presenters: Ian... Read More

Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy programs including in X-TOLE2 and X-TOLE3 clinical trials in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Xenon to host XEN1101 MDD Webinar in mid-September to discuss Kv modulation in MDD,... Read More

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover. Dr. Cannon has more than 30 years of experience in the pharmaceutical industry, where she served in business and commercial leadership roles at Merck and Co., UCB,... Read More

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023. Conference Call/Webcast Information: Date: Wednesday, August 9, 2023 Time: 4:30 pm Eastern Time (1:30 pm Pacific... Read More

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. Company Fireside Chat Presentation Details: Date: Monday, June 12, 2023 Time: 10:00 am Pacific Time (1:00 pm Eastern Time) Webcast: Register here... Read More

VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 Jefferies Healthcare Conference taking place June 7-9, 2023 in New York, NY. Company Fireside Chat Presentation Details: Date: Wednesday, June 7, 2023 Time: 9:30 am Eastern Time Webcast: Register here Presenters: Ian... Read More

VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 RBC Capital Markets Global Healthcare Conference taking place May 16-17, 2023 in New York, NY. Company Fireside Chat Presentation Details: Date: Tuesday, May 16, 2023 Time: 3:05 pm Eastern Time / 12:05 pm Pacific Time... Read More

XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last patient to be screened next month in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in fourth quarter Conference call at 4:30 pm ET today... Read More

VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2023 taking place May 9-11, 2023. Company Fireside Chat Presentation Details: Date: Wednesday, May 10, 2023 Time: 4:20 pm Pacific Time (7:20 pm Eastern Time) Presenters: Ian Mortimer,... Read More

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2023. Conference Call/Webcast Information: Date: Tuesday, May 9, 2023 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time) Dial-In:... Read More

Oral presentation by Dr. Jacqueline French to outline sustained monthly reduction in focal onset seizures during open-label extension of X-TOLE study Poster to present the trial design for Phase 3 X-ACKT clinical study evaluating XEN1101 in additional epilepsy indication of primary generalized tonic-clonic seizures VANCOUVER, British Columbia and BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.... Read More

BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held in Toronto, Ontario from April 25-26, 2023. Company Presentation Details: Date: Tuesday, April 25, 2023 Time: 11:00 am Eastern Time (8:00 am... Read More

BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20, 2023. Company Fireside Chat Presentation Details: Date: Thursday, April 20, 2023 Time: 2:15 pm Eastern Time (11:15 am Pacific Time) Presenters: Ian... Read More

BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel 2023 CNS Days taking place March 28-29, 2023. Company Fireside Chat Presentation Details: Date: Tuesday, March 28, 2023 Time: 1:00 pm Eastern Time (10:00 am Pacific Time) Presenters: Ian Mortimer, President... Read More

XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter Conference call at 4:30 pm ET today BURNABY, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today... Read More

BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 1, 2023. Conference Call/Webcast Information: Date: Wednesday, March 1, 2023 Time: 4:30 pm Eastern Time (1:30 pm... Read More

BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual SVB Securities Global Biopharma Conference taking place from February 14-16, 2023. Company Fireside Chat Presentation Details: Date: Wednesday, February 15, 2023 Time: 3:00 pm Eastern Time (12:00 pm Pacific Time)... Read More

XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026 BURNABY, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined recent progress... Read More

BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 9-12, 2023. Company Presentation Details: Date: Monday, January 9, 2023 Time: 7:30 am Pacific Time (10:30 am Eastern Time)... Read More